OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced fourth quarter and full year 2016 financial results.
“We are very pleased with our performance during the fourth quarter and throughout 2016, as we evolved from a single-product company to a multi-product company” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “Our core tuberculosis (TB) business grew ahead of our expectations, with strong growth in the U.S. market during the fourth quarter. As we look to 2017 and beyond, we expect to continue to drive top line growth through the continued strong performance of our core TB business, growth in our recently acquired tick-borne disease franchise and the introduction of products currently in development. Additionally, we are focused on progressing towards profitability through expanding margins and driving operating leverage.”
